American Society of Hirudotherapy

Deep Vein Thrombosis (Post-Acute Phase Symptoms)

Investigational use for residual symptoms in the post-acute phase of DVT (>6 weeks); contraindicated in acute DVT.

Tier C — InvestigationalInvestigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Last Updated: November 12, 2026 · ASH Editorial · based on the books

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for DVT or its post-acute symptoms. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is investigational.
What evidence exists?
Tier C (investigational). Leech therapy is STRICTLY CONTRAINDICATED in acute DVT (within 6 weeks). In the post-acute phase, no clinical study of leech therapy was identified; related reports in post-thrombotic syndrome and thrombophlebitis are small and non-randomized. There are no randomized trials. Standard care during the post-acute phase emphasizes therapeutic anticoagulation (DOAC, warfarin, or LMWH per guidelines), graduated compression stockings, leg elevation, and exercise — anticoagulation should NOT be paused for complementary therapy.
Main risks
  • Recurrent DVT or new pulmonary embolism if anticoagulation is paused — this is the dominant, potentially fatal risk
  • Bleeding from bite sites for 6 to 24 hours after detachment, magnified by any concurrent anticoagulation
  • Bruising and tenderness over the affected leg for 5 to 10 days
  • Local skin infection or, rarely, Aeromonas infection
  • Allergic reaction to leech saliva (uncommon)
  • Worsening anemia from cumulative blood loss
  • Small bite marks that usually fade over weeks to months (rarely a pale spot stays longer)
  • Delay or replacement of evidence-based anticoagulation, compression, and exercise
Who should not consider this
  • Patients within 6 weeks of acute DVT or PE diagnosis
  • Patients on active anticoagulation (DOAC, warfarin, LMWH, heparin) — anticoagulation should not be paused
  • Patients with active PE or known thrombophilia (Factor V Leiden, prothrombin gene, antiphospholipid syndrome) without hematology clearance
  • Patients with hemophilia, anemia, or active infection
  • Patients with critical limb ischemia (ABI under 0.4)
  • Pregnant patients
What to ask your clinician
  • How long is my anticoagulation indicated, and what is my recurrence risk?
  • Have I had follow-up duplex ultrasound to assess residual thrombus?
  • Am I using a properly fitted graduated compression stocking, and have I tried structured exercise?
  • Do I have features of established post-thrombotic syndrome that warrant a different approach?
  • Is my hematology team's opinion sought before any complementary therapy?
  • Anticoagulation should NOT be paused for leech therapy — does the practitioner understand this?
  • What is the practitioner's experience and Aeromonas-prevention plan?
When to seek urgent care
  • Sudden shortness of breath, sharp chest pain on inspiration, cough with blood, fainting, or rapid heart rate (possible pulmonary embolism — call 911)
  • New or worsening unilateral leg swelling, redness, and pain (recurrent DVT)
  • Sudden severe leg pain with coldness or pallor (possible arterial event)
  • Bleeding that does not stop with 30 minutes of firm pressure
  • Bleeding from a bite site lasting more than 24 to 48 hours
  • Fever above 38.0 C / 100.4 F, spreading redness, or pus
  • Hives, throat tightness, or breathing difficulty

What this does NOT mean

  • This is not FDA-cleared for DVT or post-acute DVT symptoms.
  • Small non-randomized reports from related venous conditions do NOT establish efficacy on recurrence, PTS prevention, or quality of life.
  • Mechanism rationale (rheology, anti-inflammation) does NOT replace anticoagulation.
  • Leech therapy is NEVER a substitute for evidence-based anticoagulation, compression, or exercise.
  • Anticoagulation should NOT be paused to enable leech application — recurrence risk is unacceptable.

Clinical Profile

Category
Vascular
ICD-10
I82.401, I82.402, I82.403, I82.40, I82.501
Safety tier
High

Evidence Summary

Leech therapy is STRICTLY CONTRAINDICATED in acute DVT (<6 weeks). No clinical study of leech therapy specifically in the post-acute phase of DVT was identified in PubMed, Europe PMC, Crossref or ClinicalTrials.gov; any use is investigational only. The nearest evidence is from adjacent venous conditions: an uncontrolled report of 87 patients with post-thrombotic syndrome (Eldor et al., conference abstract 1998, as summarized in Baskova and Isakhanyan 2004), a Russian comparison in acute lower-limb thrombophlebitis (Magomedov 1998; 26 patients given leeches plus standard care versus 20 given standard care), and single case reports. This residual symptom phase (>6 weeks, on stable anticoagulation) overlaps significantly with post-thrombotic syndrome (listed separately as Tier C, investigational). The distinct entry here reflects the residual symptom phase between acute DVT and established PTS. Anticoagulation must be reviewed before any leech application — most DOACs and warfarin are absolute contraindications.

What the books describe

Below is a summary of what books on hirudotherapy say about this condition. These are the authors’ observations, not a proven effect and not a promise of results. Hirudotherapy has contraindications; the decision is made by a physician.

  • Baskova and Isakhanyan do not write about the period after acute deep vein thrombosis as a separate condition and do not name a time since the thrombosis; they write about deep vein thrombosis itself as a potentially life-threatening disease (the clot can break off and block branches of the pulmonary artery); the closest thing in their text is postphlebitic syndrome, which, according to them (citing Eldor and colleagues, 1998), is found in some of the patients suffering from deep vein thrombosis of the legs; these sentences say nothing about treating such a thrombosis with leeches[B1].
  • Michalsen et al. write that using leeches as a supportive treatment in acute deep vein thrombosis of the legs cannot be justified: blood-thinning medicines at the start of treatment are a contraindication to leeches[B3].
  • In postphlebitic syndrome after such a thrombosis, Michalsen et al. allow leeches only as a superficial supportive treatment and only after drug anticoagulant therapy has ended; they do not name a time in weeks[B3].
  • They also write that in deep vein thrombosis the systemic effect of leeches is insufficient, so it has to be assumed that they have no relevant systemic fibrinolytic activity; in thrombosis and coronary syndromes, insufficient proof of efficacy, insufficient pharmacological standardization and insufficient controllability, in their words, rule out the use of leeches, and for the prevention and treatment of thrombosis heparin and coumarins are preferred, medicines with a reliable and controllable action[B3].
  • In their list of contraindications, Baskova and Isakhanyan name, among other things, hemophilia, hemorrhagic diatheses, anemias and the simultaneous prescription of anticoagulants, that is, medicines that thin the blood (especially long-term and daily use); Flecken and Michalsen call any hemophilia and the simultaneous use of anticoagulants (Marcumar, warfarin, heparin and heparinoids are named) an absolute contraindication, and in anemia, in their words, treatment involving blood loss is generally contraindicated[B1][B3].
  • Flecken and Michalsen do not regard aspirin and clopidogrel as contraindications in themselves, but advise placing fewer leeches at the first treatment and asking the patient about a tendency to bleed[B3].
  • Separately from leeches, Baskova and Isakhanyan describe the medicine Piyavit — a powder of dried leeches in gelatin capsules, taken by mouth — and stress that its mechanism of action is fundamentally different from the action of saliva when leeches are placed[B1].

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)

Contraindications

  • Hemophilia or another bleeding disorder
  • Taking anticoagulants (blood thinners such as warfarin or heparin)
  • Anemia or suppressed blood formation
  • Low blood pressure, shock, collapse or fainting
  • Severe wasting (cachexia)
  • Intolerance of leeches or a history of severe allergic reactions
  • Pregnancy
  • Stomach or duodenal ulcer, erosive gastritis
  • Acute infectious disease or high fever
  • Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
  • Drinking alcohol at the time of treatment
  • No consent from the patient
  • Active deep vein thrombosis (acute phase)
  • Critical limb ischemia (ABI <0.4)
  • Active anticoagulation therapy
  • Acute or recent (<6 weeks) DVT
  • Active pulmonary embolism within 3 months

Related Conditions

References

  • [B1]

    Баскова И.П., Исаханян Г.С. Гирудотерапия. Наука и практика [Hirudotherapy: Science and Practice]

    Москва: Монолит(2004)https://search.rsl.ru/ru/record/01007959553

    Monograph in Russian, 506 pp., ISBN 5-89527-058-1. Chapter 15: sensation at the bite, length of the session; secretion kininases and pain.

  • [B3]

    Michalsen A., Roth M., Dobos G. Medicinal Leech Therapy

    Stuttgart — New York: Thieme(2007)https://books.google.com/books?vid=ISBN9781588905635

    ISBN 978-3-13-143581-1 / 978-1-58890-563-5. Chapter 9, p. 107: perceptions of the bite — a local dragging pain lasting around one to five minutes.

The information on this page is based on the hirudotherapy books listed under References and reflects the experience their authors describe. Sensations and results differ from person to person. This information is not medical advice, a diagnosis or a prescription, and it does not replace an examination by a physician. Do not stop or change any prescribed treatment without your physician. Hirudotherapy has contraindications.

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.